David Givol
#129,173
Most Influential Person Now
David Givol's AcademicInfluence.com Rankings
David Givolbiology Degrees
Biology
#8396
World Rank
#11465
Historical Rank
Biotechnology
#105
World Rank
#107
Historical Rank
Computational Biology
#159
World Rank
#159
Historical Rank
Download Badge
Biology
David Givol's Degrees
- PhD Biomedical Sciences Weizmann Institute of Science
- Masters Biotechnology Tel Aviv University
- Bachelors Biotechnology Tel Aviv University
Why Is David Givol Influential?
(Suggest an Edit or Addition)David Givol's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Outcome signature genes in breast cancer: is there a unique set? (2004) (867)
- Induction of WAF1/CIP1 by a p53-independent pathway. (1994) (831)
- Participation of p53 cellular tumour antigen in transformation of normal embryonic cells (1984) (762)
- Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). (1993) (567)
- Localization of gene for human p53 tumour antigen to band 17p13 (1986) (500)
- Complexity of FGF receptors: genetic basis for structural diversity and functional specificity (1992) (444)
- Developmental expression of two murine fibroblast growth factor receptors, flg and bek. (1991) (410)
- The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). (1986) (368)
- Developmental expression of c-kit, a proto-oncogene encoded by the W locus. (1990) (366)
- DNA microarrays identification of primary and secondary target genes regulated by p53 (2001) (361)
- Sequence of chicken ovalbumin mRNA (1978) (332)
- Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. (2004) (264)
- MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. (2008) (245)
- PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. (2008) (242)
- The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. (1989) (239)
- Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. (2010) (239)
- A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. (1999) (215)
- Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. (1985) (208)
- Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element (1982) (195)
- A single gene and a pseudogene for the cellular tumour antigen p53 (1983) (188)
- DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1 (2001) (184)
- Functional analysis of the ligand binding site of EGF‐receptor utilizing chimeric chicken/human receptor molecules. (1989) (181)
- Analysis of the gene coding for the murine cellular tumour antigen p53. (1984) (176)
- Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG). (1989) (169)
- All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. (1989) (164)
- Cloning and expression of a widely expressed receptor tyrosine phosphatase. (1990) (160)
- The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction (1995) (160)
- Localization of antibody-combining sites within the variable portions of heavy and light chains. (1972) (159)
- Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha (1988) (159)
- Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin (1999) (157)
- A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. (1992) (156)
- Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. (1988) (153)
- Nucleotide sequence of the rat skeletal muscle actin gene (1982) (149)
- Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells (2006) (148)
- Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses* (2002) (147)
- Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. (1992) (142)
- Activation of the c-mos oncogene in a mouse plasmacytoma by insertion of an endogenous intracisternal A-particle genome. (1983) (142)
- Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells (2010) (137)
- A specific combination of substrates is involved in signal transduction by the kit‐encoded receptor. (1991) (137)
- An active antibody fragment (Fv) composed of the variable portions of heavy and light chains. (1973) (137)
- General Method for the Detection of Cells producing Antibodies against Haptens and Proteins (1970) (136)
- Nucleotide sequence analysis identifies the human c-sis proto-oncogene as a structural gene for platelet-derived growth factor (1984) (129)
- The 5′ region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. (1985) (128)
- Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. (1992) (124)
- DISULFIDE INTERCHANGE AND THE THREE-DIMENSIONAL STRUCTURE OF PROTEINS. (1965) (119)
- Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs (1998) (114)
- Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. (2000) (114)
- Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling (1988) (114)
- KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. (1993) (112)
- Steel factor and c-kit protooncogene: genetic lessons in signal transduction. (1994) (110)
- Purification and properties of an enzyme from beef liver which catalyzes sulfhydryl-disulfide interchange in proteins. (1966) (110)
- FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. (2008) (108)
- Diversity of germ-line immunoglobulin VH genes (1981) (108)
- "Retroposon" insertion into the cellular oncogene c-myc in canine transmissible venereal tumor. (1985) (106)
- A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. (1994) (104)
- Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. (1993) (104)
- Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer (2003) (103)
- Kinetic mapping of the antibody combining site by chemical relaxation spectrometry. (1974) (103)
- Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs (2011) (100)
- A rennin-sensitive bond in αs1 Β-casein (1974) (99)
- Profile of gene expression regulated by induced p53: connection to the TGF‐β family (2000) (99)
- A two-stage cleavage of rabbit gamma-globulin by a water-insoluble papain preparation followed by cysteine. (1961) (99)
- Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo (2010) (97)
- Evolutionary aspects of immunoglobulin heavy chain variable region (VH) gene subgroups. (1983) (96)
- The murine flg gene encodes a receptor for fibroblast growth factor. (1990) (94)
- A novel form of FGF receptor‐3 using an alternative exon in the immunoglobulin domain III (1993) (91)
- Antigen-induced conformational changes in antibodies and their Fab fragments studied by circular polarization of fluorescence. (1975) (90)
- The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes (2006) (89)
- A general method for the specific isolation of peptides containing modified residues, using insoluble antibody columns. (1971) (88)
- Localization of affinity-labeled residues on the heavy and light chain of two myeloma proteins with anti-hapten activity. (1972) (86)
- Organization and evolution of immunoglobulin VH gene subgroups. (1982) (85)
- Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas (1983) (85)
- Interspecies molecular chimeras of kit help define the binding site of the stem cell factor (1993) (85)
- HIPK2 modulates p53 activity towards pro-apoptotic transcription (2009) (85)
- Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53 (2007) (83)
- Identification of a hexapeptide that mimics a conformation-dependent binding site of acetylcholine receptor by use of a phage-epitope library. (1993) (80)
- Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation (1987) (80)
- A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1 (2002) (79)
- Homology between an endogenous viral LTR and sequences inserted in an activated cellular oncogene (1983) (79)
- Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). (1994) (78)
- Nanog transforms NIH3T3 cells and targets cell-type restricted genes. (2006) (78)
- Structure of an antibody combining site by magnetic resonance (1977) (77)
- Design principle of gene expression used by human stem cells: implication for pluripotency (2004) (77)
- Multiple structural elements determine ligand binding of fibroblast growth factor receptors. Evidence that both Ig domain 2 and 3 define receptor specificity. (1993) (75)
- Skeletal muscle actin mRNA. Characterization of the 3' untranslated region. (1981) (74)
- Model-building studies of antigen-binding sites: the hapten-binding site of mopc-315. (1977) (73)
- Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. (2008) (72)
- A general method for the isolation of labelled peptides from affinity-labelled proteins. (1970) (72)
- The nucleotide sequence of rat α-tubulin: 3'-end characteristics, and evolutionary conservation (1981) (68)
- Simple DNA sequences in homologous flanking regions near immunoglobulin VH genes: a role in gene interaction? (1982) (68)
- Induction of anti-idiotypic antibodies by immunisation with syngeneic spleen cells educated with acetylcholine receptor (1978) (67)
- Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. (2010) (67)
- T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A--L-specific helper factor (1980) (66)
- CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. (2005) (64)
- Comparison of the C-terminal Amino-acid Sequence of Two Horse Immunoglobulins IgG and IgG(T) (1966) (64)
- Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. (1993) (63)
- Selective participation of immunoglobulin V region and major histocompatibility complex products in antigen binding by T cells (1978) (62)
- Affinity labeling and cross-linking of the heavy and light chains of a myeloma protein with anti-2,4-dinitrophenyl activity. (1971) (59)
- The gene and the pseudogene for mouse p53 cellular tumor antigen are located on different chromosomes (1984) (59)
- Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. (2009) (58)
- Mechanism of activation of the mouse c‐mos oncogene by the LTR of an intracisternal A‐particle gene. (1984) (58)
- Dynamics of hapten-antibody interaction. Studies on a myeloma protein with anti-2,4-dinitrophenyl specificity. (1972) (58)
- Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. (1991) (57)
- A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses. (1992) (56)
- Vascular gene expression and phenotypic correlation during differentiation of human embryonic stem cells (2005) (54)
- Conformational changes induced in a homogeneous anti-type III pneumococcal antibody by oligosaccharides of increasing size. (1975) (54)
- PCR-based identification of new receptors: molecular cloning of a receptor for fibroblast growth factors. (1991) (53)
- Expression of the bcl‐2 gene in mouse B lymphocytic cell lines is differentiation stage specific (1987) (53)
- Preparation and characterization of anti‐framework antibodies to the heavy chain variable region (VH) of mouse immunoglobulins (1978) (52)
- Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras‐dependent up‐regulation of KGF expression (2004) (52)
- Crystallization with hapten of the Fab' fragment from a mouse IgA myeloma protein with antidinitrophenyl activity. (1971) (52)
- Isolated hapten‐binding receptors of sensitized lymphocytes. IV. Expression of immimoglobulin variable regions in (4‐hydroxy‐3‐nitrophenyl) acetyl (NP)‐specific receptors isolated from murine B and T lymphocytes (1979) (52)
- BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. (2005) (51)
- OXIDATION AND DISULFIDE INTERCHANGE IN THE REACTIVATION OF REDUCED RIBONUCLEASE. (1964) (51)
- Targeting Hypoxia in Cancer Cells by Restoring Homeodomain Interacting Protein-Kinase 2 and p53 Activity and Suppressing HIF-1α (2009) (51)
- A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia. (1989) (50)
- Structural organization of the murine c-kit proto-oncogene. (1992) (49)
- Flg-2, a new member of the family of fibroblast growth factor receptors. (1991) (48)
- The C-terminal peptide of the heavy chain of the rabbit immunoglobulin IgG. (1965) (48)
- Preparation of Fv fragment from the mouse myeloma XRPC-25 immunoglobulin possessing anti-dinitrophenyl activity. (1976) (48)
- Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function (2012) (47)
- HIPK2--A therapeutical target to be (re)activated for tumor suppression: Role in p53 activation and HIF-1α inhibition (2010) (47)
- The minimal antigen-binding fragment of antibodies--Fv fragment. (1991) (47)
- Common origin of transmissible venereal tumors (TVT) in dogs. (1987) (46)
- Localization of idiotypic antigenic determinants in the Fv region of murine myeloma protein MOPC-315. (1973) (46)
- Isolation of antibodies to antigens of low molecular weight. (1962) (45)
- The fractionation of immunoglobulins with insolubilized concanavalin A. (1972) (43)
- Structure‐function analyses of the kit receptor for the steel factor (1993) (42)
- Expression of human serum albumin in the milk of transgenic mice (1992) (42)
- Specific Blocking in vitro of Antibody Synthesis by Affinity Labelling Reagents (1969) (41)
- Folding and interaction of subunits at the antibody combining site. (1976) (41)
- S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation (2006) (41)
- CD133‐Positive Hematopoietic Stem Cell “Stemness” Genes Contain Many Genes Mutated or Abnormally Expressed in Leukemia (2005) (40)
- Comparison of EGF receptor sequences as a guide to study the ligand binding site. (1991) (39)
- Recovery of antibody activity upon reoxidation of completely reduced polyalanyl heavy chain and its Fd fragment derived from anti-2,4-dinitrophenyl antibody. (1968) (39)
- Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells. (1996) (37)
- Correlated expression of VH framework and VHidiotypic determinants on T helper cells and on functionally undefined T cells binding group A streptococcal carbohydrate (1980) (37)
- RESOLUTION OF RABBIT GAMMA-GLOBULIN INTO TWO FRACTIONS BY CHROMATOGRAPHY ON DIETHYLAMINOETHYL-SEPHADEX. (1963) (37)
- Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen. (1983) (37)
- LGR5 and Nanog identify stem cell signature of pancreas beta cells which initiate pancreatic cancer. (2013) (36)
- The combining site of the dinitrophenyl-binding immunoglobulin A myeloma protein MOPC 315. (1977) (35)
- Affinity labeling of anti-dinitrophenyl antibodies with bromoacetyl derivatives of homologous haptens. (1969) (34)
- Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity (1988) (34)
- The cDNA sequence and gene analysis of the human pim oncogene. (1987) (33)
- Promoter and enhancer elements in the rearranged alpha chain gene of the human T cell receptor. (1987) (32)
- Cloning and expression of the variable regions of mouse myeloma protein MOPC315 in E. coli: recovery of active FV fragments. (1992) (32)
- A homologous series of affinity labeling reagents and their use in the study of antibody binding sites. (1971) (32)
- The tumor suppression function of p21Waf is contained in its N-terminal half ('half-WAF'). (1995) (31)
- Efficient in vitro and in vivo expression of human glucocerebrosidase cDNA. (1987) (31)
- The position of various cleavages of rabbit immunoglobulin G. (1968) (31)
- The binding of complement by complexes formed between a rabbit antibody and oligosaccharides of increasing size. (1976) (30)
- A rapid assay for drug sensitivity of glioblastoma stem cells. (2007) (29)
- Isolation of nitrotyrosine-containing peptides by using an insoluble-antibody column. (1971) (29)
- Overexpression of human p21waf1/cip1 arrests the growth of chicken embryo fibroblasts transformed by individual oncogenes. (1995) (29)
- Affinity labeling of the heavy and light chains of a myeloma protein with anti-2,4-dinitrophenyl activity. (1970) (29)
- Promoter region of the murine fibroblast growth factor receptor 2 (bek/KGFR) gene. (1992) (28)
- Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation (2011) (28)
- Mapping of the bcl-2 oncogene on mouse chromosome 1. (1988) (27)
- Allelic immunoglobulin VH genes in two mouse strains: possible germline gene recombination. (1983) (27)
- Cross-reactive idiotypic determinants on murine anti-(T,G)-A--L antibodies. (1978) (26)
- H-2-restricted helper factor secreted by clone hybridoma cells (1981) (26)
- The gross architecture of an antibody-combining site as determined by spin-label mapping. (1977) (26)
- Molecular modeling based mutagenesis defines ligand binding and specificity determining regions of fibroblast growth factor receptors. (1995) (25)
- Alloactivated Lyt 1 +2− T lymphoblasts bind syngeneic Ia antigens (1980) (25)
- Domain deletion in the extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression. (1990) (24)
- Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene (1990) (24)
- Soluble complexes of antigen and antibody fragments. (1962) (23)
- Mapping of murine fibroblast growth factor receptors refines regions of homology between mouse and human chromosomes. (1994) (23)
- [11] Haloacetyl derivatives (1977) (23)
- Localization of the stem cell markers LGR5 and Nanog in the normal and the cancerous human ovary and their inter-relationship. (2013) (23)
- HIPK2 downregulates vimentin and inhibits breast cancer cell invasion (2012) (23)
- Common peptides from the N-terminal half of heavy chain of immunoglobulin G from normal rabbit serum and a specific antibody. (1968) (23)
- Allotype-linked genetic control of a polymorphic VH framework determinant on mouse T-helper cell receptors (1980) (23)
- Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes (2003) (22)
- Conservation and divergence of immunoglobulin VH pseudogenes. (1983) (22)
- Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells. (1994) (21)
- Preparation and characterization of antibodies to the λ chain variable region (Vλ) of mouse immunoglobulins (1978) (21)
- Comparison of the fine specificity of anti-dinitrophenyl-combining site composed of either VL dimer or VL and VH of protein 315. (1977) (21)
- Antibodies to immunoglobulin heavy chain variable regions protect helper cells from specific suicide by radiolabeled antigen (1980) (21)
- A rennin-sensitive bond in alpha-s1 B-casein. (1974) (20)
- Rearrangement and expression of the alpha- and beta-chain genes of the T-cell antigen receptor in functional murine suppressor T-cell clones. (1985) (19)
- p53 reactivation (2012) (19)
- Nanog inhibits the switch of myogenic cells towards the osteogenic lineage. (2008) (17)
- Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11 (1980) (17)
- Immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukaemia: correlation with clinical stage (1989) (17)
- Apoptosis of granulosa cells and female infertility in achondroplastic mice expressing mutant fibroblast growth factor receptor 3G374R. (2001) (17)
- A COMPARISON OF FRAGMENTS OF RABBIT ANTIBODIES AND NORMAL GAMMA-GLOBULIN BY THE PEPTIDE-MAP TECHNIQUE. (1964) (16)
- Differential localization of LGR5 and Nanog in clusters of colon cancer stem cells. (2013) (16)
- Solubilization of lymphocyte and thymocyte antigens by a reversible chemical modification (1971) (16)
- Interactions of the lanthanide- and hapten-binding sites in the Fv fragment from the myeloma protein MOPC 315. (1976) (16)
- ISOLATION AND FRAGMENTATION OF ANTIBODIES TO POLYTYROSYL GELATIN. (1964) (16)
- Goat immunolobulin G. Peptide chains and terminal residues. (1969) (15)
- Inactivation of glyceraldehyde 3‐phosphate dehydrogenase by a bifunctional reagent (1969) (15)
- The binding of 2,4,6-trinitrophenyl derivatives to the mouse myeloma immunoglobulin A protein MOPC 315. (1978) (15)
- Preparation and subfractionation of isologous and heterologous anti-idiotypes, using FV fragments. (1976) (15)
- The chemical structure of the heavy chains of rabbit and human immunoglobulin G (IgG) (1966) (15)
- The carboxyl terminal amino acids of rabbit gamma-globulin. (1962) (14)
- Affinity labeling and topology of the antibody combining site. (1974) (14)
- Circular dichroism study of the antibody combining site. (1973) (14)
- Counteracting MDM2‐induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells (2010) (13)
- Interchain disulfide bonds of goat immunoglobulin G. (1971) (13)
- IMMUNOLOGIC PROPERTIES OF URINARY PREPARATIONS OF HUMAN MENOPAUSAL GONADOTROPINS, WITH SPECIAL REFERENCE TO PERGONAL (1961) (12)
- H2O2‐induced apoptotic death in serum‐deprived cultures of oligodendroglia origin is linked to cell differentiation (1999) (12)
- A blocked N-terminal residue in the light chain of rabbit immunoglobulin G. (1968) (12)
- The role of nitro groups in the binding of nitroaromatics to protein MOPC 315. (1978) (12)
- Promoter mutations that allow nifA-independent expression of the nitrogen fixation nifHDKY operon. (1983) (12)
- Overexpression of p21waf1/cip1 arrests the growth of chicken embryo fibroblasts that overexpress E2F1 (1998) (11)
- Retention and loss of immunoglobulin heavy chain alleles in helper T cell hybridoma clones. (1983) (11)
- On the location of palindromes in immunoglobulin genes. (1977) (11)
- Comparison of the dimensions of the combining sites of the dinitrophenyl-binding immunoglobulin A myeloma proteins MOPC 315, MOPC 460 and XRPC 25 by spin-label mapping. (1977) (11)
- Modulation of c-kit expression in pancreatic adenocarcinoma: a novel stem cell marker responsible for the progression of the disease. (2014) (11)
- Effect of limited digestion by proteolytic enzymes on Escherichia coli beta-galactosidase. (1966) (11)
- Specificity of interactions of hapten side chains with the combining site of the myeloma protein MOPC 315. (1977) (10)
- Ligand binding by fibroblast growth factor receptors investigated using chimeric receptor molecules. (1995) (10)
- Analysis of immunoglobulin mRNA in murine myeloma cell variants defective in the synthesis of the light or heavy polypeptide chains. (1982) (9)
- Preparation of a semisynthetic antibody. (1978) (9)
- Structure and activity of the translocated c-myc in mouse plasmacytoma XRPC-24. (1986) (8)
- Conformational flexibility of an antibody combining site composed of two identical V regions (1978) (8)
- Folding, association, and interactions of domains in the antibody molecule. (1977) (8)
- Variable region (Fv) determinants on mouse lymphocytes. (1976) (7)
- Induced p 53 expression in lung cancer cell line promotes cell senescence and di erentially modi ® es the cytotoxicity of anti-cancer drugs (1998) (7)
- Structural analysis of the antibody combining site. (1973) (7)
- The effect of large doses of thiourea on the composition of the liver and urine of rats. (1956) (6)
- Activation of oncogenes by transposable elements. (1986) (6)
- Simultaneous expression of mu‐ and gamma‐chain mRNA in cloned murine B‐lymphoma cell lines. (1983) (6)
- Subunit interaction in antibodies and antibody fragments studied by circular polarization of fluorescence (1975) (6)
- The cleavage of rabbit immunoglobulin G by trypsin after mild reduction and aminoethylation. (1967) (6)
- Antibody specificity: a 270-MHz hydrogen-1 nuclear magnetic resonance study of the binding of dinitrophenyl compounds to the VL dimer of protein 315. (1981) (5)
- BCL 6 is regulated by p 53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma (2005) (5)
- Structure of immunoglobulin γ2b heavy chain gene cloned from mouse embryo gene library (1980) (5)
- The importance of the two halves of human immunoglobin light chain in recombination with the heavy chain. (1967) (5)
- Expression of the murine proto-oncogene bcl-2 is stage specific and cell-type specific. (1988) (4)
- Two Ig framework I epitopic specificities recognized by a rabbit antiserum and a monoclonal antibody to mouse VH chains. (1990) (4)
- Affinity labeling anti-p-azobenzenearsonate antibodies using bromoacetyl derivatives of homologous hapten. (1973) (4)
- The nucleotide sequence of rat alpha-tubulin: 3'-end characteristics, and evolutionary conservation. (1981) (4)
- Polymorphism of human immunoglobulin VH genes: a possible marker of autoimmune disease. (1987) (4)
- Specific spin labeling of the Fc region of immunoglobulins. FEBS Lett. 80, 133 (1977) (4)
- Specific isolation of peptides containing modified tyrosine residues on insoluble antibody column. (1972) (4)
- Differences in the constitution of antibody combining site in different mice strains (1972) (4)
- Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11. (1980) (4)
- Preparation and characterization of anti-framework antibodies to the kappa-chain variable region (V kappa) of mouse immunoglobulins. (1980) (4)
- Affinity labeling of antibody combining sites as illustrated by anti-dinitrophenyl antibodies. (1977) (4)
- Disc electrophoresis patterns of the Fd fragment of rabbit immunoglobulin fractions and of purified antibodies. (1969) (3)
- On the role of Tyr 34L in the antibody combining site of the dinitrophenyl binding protein 315. (1979) (3)
- Comparison by1H NMR of the hapten environment in the combining site of the dinitrophenyl binding IgA protein 315 and its fragments (1978) (3)
- Asparagine-344 is a key residue for ligand binding in keratinocyte growth factor receptor. (1996) (3)
- Affinity cross-linking of heavy and light chains. (1977) (2)
- N.m.r. investigation of hapten binding to the myeloma protein M460 (1980) (2)
- Haloacetyl derivatives. (1977) (2)
- PROCEDURES FOR SENSITIVE IMMUNOASSAY. (1970) (2)
- Transposable elements and cancer. (1986) (2)
- Antigen-binding receptors on T cells from long-term MLR. Evidence of binding sites for allogeneic and self-MHC products (2005) (2)
- Combining site and antigenic determinants of the V regions. (1978) (1)
- p53's Dilemma in Transcription: Analysis by Microarrays (2010) (1)
- Insertional mutagenesis and breast carcinoma (1988) (1)
- Receptor Functions andLigand-Dependent Transforming Potential ofa Chimeric kitProto-Oncogene (1990) (1)
- Monoclonal antibody specific to human epidermal growth factor receptor and therapeutic agent using the same (1989) (0)
- The Kit Receptor for the Stem Cell Factor: Genetic Lessons in Signal Transduction (1992) (0)
- Primary and secondary target genes regulated by p53 identified by DNA microarrays (2001) (0)
- Rearrangement and Activation of a Cellular Oncogene (1984) (0)
- Activation of a cellular oncogene () by DNA transposition (1983) (0)
- Identification of a neutralizing antibody determinant on basic fibroblast growth factor by screening a random phage‐epitope library (1995) (0)
- Organization and evolution of immunoglobulin VH gene subgroups ( deletion mapping / gene expansion / sequences of human VHIlI genes (0)
- Cloning and expression of a widely expressed receptor tyrosine phosphatase ( surface receptors / dephosphorylation / signal transduction ) (0)
- Hematopoietic Stem Cells “Stemness” Genes Contain Many Genes Mutated or Abnormally Expressed in Hematopoietic Malignancies. (2004) (0)
- Structure of immunoglobulin gamma 2b heavy chain gene cloned from mouse embryo gene library. (1980) (0)
- Therapeutic compositions containing monoclonal antibodies against the human receptor for epidermal growth factor (1989) (0)
- Allotype-linked genetic control of a polymorphic VH framework framework determinant on mouse T-helper cell receptors. (1980) (0)
- Activation of the cmos oncogene in a mouse plasmacytoma by insertion of an endogenous intracisternal A-particle genome ( cellular oneogene / endogenous retroviruses / transposition / repetitive cellular elements ) (1999) (0)
- Ligand-bond determining region in fibroblast receptor conferring ligand specificity (1992) (0)
- Comparison by 1H NMR of the hapten environment in the combining site of the dinitrophenyl binding IgA protein 315 and its fragments. (1978) (0)
- Monoclonal antibodies against the receptor of the epidermal growth factor and those containing therapeutic preparations. (1989) (0)
- Stem Cells, Cancer Stem Cells I. Leukemia stem cells II. Stem cell transcription factors (2006) (0)
- receptor monoclonal antibodies specific growth factor of human epidermis and therapeutic compositions containing them. (1989) (0)
- Meetings: Report on the conference ‘Oncogenes, cell growth, and cancer’ (1985) (0)
- Anti‐V region framework antibodies affect the ligand binding of VL dimer (1979) (0)
- Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPCH (2004) (0)
- Figure 1, [Gene expression patterns identified from...]. (2013) (0)
- Advances in Brief Induction of WAFJ / CIP 1 by a p 53-independent Pathway ' (2006) (0)
- The Combining Site of Antibodies: From the Protein to the Gene (1984) (0)
- Book reviewsAntibody engineering. A Practical guide: Edited by Carl A. K. Borrebaeck. W. H. Freeman and Company, New York, 1991. 180pp.$27.95 (1992) (0)
- (rearranged c-myc/repetitive DNA/transposable element/Kpn I famil: (2016) (0)
- Specific Blocking of in vitro Antibody Response by Affinity Labeling Reagents (1970) (0)
- Binding of histamine- and other ligand-conjugated macromolecules to lymphocytes (1975) (0)
- Characterization and specificity of a T-cell cooperative factor. (1976) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Givol?
David Givol is affiliated with the following schools:
